These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1698237)

  • 1. Fludarabine monophosphate for prolymphocytic leukaemia.
    Smith OP; Mehta AB
    Lancet; 1990 Sep; 336(8718):820. PubMed ID: 1698237
    [No Abstract]   [Full Text] [Related]  

  • 2. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
    Cervantes F; Salgado C; Montserrat E; Rozman C
    Lancet; 1990 Nov; 336(8723):1130. PubMed ID: 1700245
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
    Leiby JM; Grever MR; Staubus AE; Neidhart JA; Malspeis L
    J Natl Cancer Inst; 1988 May; 80(6):447-9. PubMed ID: 2452888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained response of refractory prolymphocytic leukemia to fludarabine.
    Sporn JR
    Acta Haematol; 1991; 85(4):209-11. PubMed ID: 1853684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
    Maeda A; Iwai K; Ishibashi T
    Rinsho Ketsueki; 2009 Aug; 50(8):658-62. PubMed ID: 19915381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine shows promise for some leukemia patients.
    Oncology (Williston Park); 1989 Mar; 3(3):14. PubMed ID: 2484283
    [No Abstract]   [Full Text] [Related]  

  • 7. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
    Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine therapy in macroglobulinemic lymphoma.
    Kantarjian HM; Alexanian R; Koller CA; Kurzrock R; Keating MJ
    Blood; 1990 May; 75(10):1928-31. PubMed ID: 1692487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of fludarabine phosphate in patients with recurrent glioma.
    Cascino TL; Brown LD; Morton RF; Everson LK; Marschke RF; Dinapoli RP; O'Fallon JR
    Am J Clin Oncol; 1988 Oct; 11(5):586-8. PubMed ID: 2459951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
    Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic analysis of the ip administration of fludarabine phosphate in the swine.
    Weiss GR; Gaskill HV; Phillips JL
    Cancer Treat Rep; 1986 Apr; 70(4):499-502. PubMed ID: 2421893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report.
    Yanai M; Maeda A; Watanabe N; Sugimoto N; Matsushita A; Nagai K; Oida T; Takahashi T
    Int J Hematol; 2004 Feb; 79(2):174-7. PubMed ID: 15005347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary toxicity associated with fludarabine monophosphate.
    Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
    Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
    Kraut EH; Crowley JJ; Grever MR; Keppen MD; Bonnet JD; Hynes HE; Salmon SE
    Invest New Drugs; 1990 May; 8(2):199-200. PubMed ID: 1696569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.
    Von Hoff DD; Dahlberg S; Hartstock RJ; Eyre HJ
    J Natl Cancer Inst; 1990 Aug; 82(16):1353-5. PubMed ID: 1696322
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.
    Ajani JA; Abbruzzese JL; Faintuch JS; Blackburn R; Levin B; Boman BM
    Invest New Drugs; 1988 Apr; 6(1):47-50. PubMed ID: 2457566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
    Pillay GS; Wood L; Jacobs P
    S Afr Med J; 1996 Aug; 86(8):949-51. PubMed ID: 8823419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
    List AF; Kummet TD; Adams JD; Chun HG
    Am J Med; 1990 Sep; 89(3):388-90. PubMed ID: 1697447
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic hepatitis B and adenine arabinoside monophosphate (Ara-AMP).
    Novick DM
    Ann Intern Med; 1988 Mar; 108(3):492-3. PubMed ID: 2449111
    [No Abstract]   [Full Text] [Related]  

  • 20. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Aug; 10(4):341-3. PubMed ID: 2441592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.